Bibcol to produce 1 crore doses of Covaxin per month at Bulandshahr plant in UP

Bibcol will produce 1 crore Covaxin doses every month, starting September, at its plant in Bulandshahr. The production capacity will be increased to 2 crore doses per month in the future. The Union Health Ministry has said it will provide Rs 30 crore to Bibcol for the production of Covaxin.

Amid a shortage of anti-coronavirus vaccines in India, the Centre has given its nod for manufacturing of Covaxin by Bibcol at its plant in Uttar Pradesh’s Bulandshahr. Covaxin is an indigenous vaccine developed by Bharat Biotech. [Press release] Government Supports Augmentation of Manufacturing Capacity for COVAXIN production under Mission COVID SurakshaFor more information: https://t.co/QV5oVVGkUm@drharshvardhan @RenuSwarup #IndiaFightsCOVID19 #DBTFightsCOVID19 pic.twitter.com/V089Ocdqka Glad to share a very positive development from us 20/5/21 pic.twitter.com/cA3ZZx8pdc The Bharat Immunologicals and Biologicals Corporation Limited (Bibcol), a PSU of the Centre, is expected to produce 1 crore doses of Covaxin every month, starting September. The production capacity will be increased to two crore in the coming days, officials have said. “The unit currently produces 60% of India’s polio vaccines. The plant has facilities to store the coronavirus vaccine and cold chain infrastructure,” Bibcol Vice Chairman Rajiv Kumar Shukla told Aaj Tak.